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I _  
Abstract We have examined the regulation of precursor of 
matrix metalloproteinase 9 (proMMP-9)lprogelatinase B pro- 
duction by tumor necrosis factor et (TNFet) and interleukin let 
(H- let)  using human uterine cervical fibroblasts. TNF~ but not 
I L - la ,  induces the production of proMMP-9 in the cervical cells. 
IL--let, however, suppresses the TNFet-ioduced proMMP-9 
production. 12-O-tetradeeanoylphorbol 13-acetate (TPA) also 
stimulates the cervical cells to produce proMMP-9, and IL-let 
synergistically enhances its production. TNFet-induced 
proMMP-9 production is not mediated by protein kinase C 
(PKC), whereas the effect of IL - la  is through PKC. By contrast, 
proMMP-31prostromelysin 1 is up-regulated by TNFet or TPA 
in the presence of I L - I~  whose modulation is PKC-dependent. 
The suppressive ffect of IL - la  on the TNFet-induced proMMP- 
9 production is a new biological effect of IL-1 on MMP 
production. 
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1. Introduction 
Vlatrix metalloproteinase 9 (MMP-9)/gelatinase B is a 
mcmber of the MMP family. The enzyme has been isolated 
and characterized from a number of different cell types [1-3]. 
Tt~e expression of MMP-9 is implicated to both physiological 
an.t pathological breakdown of the connective tissue during 
invasion of cytotrophoblasts [4], the detachment of epithelial 
cells from basement membrane in the wound healing process 
[5  chronic inflammation such as rheumatoid arthritis [6,7] 
and tumor cell invasion and metastasis [8]. 
Fhe synthesis of proMMP-9 has been shown to be regu- 
lated by 12-O-tetradecanoylphorbol 13-acetate (TPA), inter- 
le~ kin 1 (IL-I), tumor necrosis factor a (TNFa)  and trans- 
fo~'ming growth factor 131 in various cell lines [1,5-8]. 
H ~wever, little evidence has been provided for the combined 
el~ act of those cytokines on the production of proMMP-9. 
In the present study, we have examined the effects of TNF~ 
avd IL-lcc on the synthesis of proMMP-9 using cultured hu- 
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man uterine cervical fibroblasts. Here we demonstrate that the 
production of proMMP-9 is markedly induced by TNFcc, but 
not by IL-lc~. On the other hand, the TNFc~-induced 
proMMP-9 production is effectively suppressed by IL- lcc 
2. Materials and methods 
2.1. Cytokines and reagents 
Recombinant human TNFcc (rhTNFc~; 2.55× 106 U/mg) and re- 
combinant human IL-I~ (rhlL-1oc; 2x 107 U/mg) were kindly sup- 
plied by Dainippon Pharmaceutical Co., Suita, Osaka, Japan. MEM 
was purchased from Life Technologies, Inc., Grand Island, NY. Fetal 
bovine serum was from Whittaker Bioproducts Inc., Walkersville, 
MD. TPA, alkaline phosphatase-conjugated donkey anti-(sheep 
IgG)IgG, 5-bromo-4-chloro-3-indolyl phosphate, Nitro Blue Tetrazo- 
lium and staurosporine were from Sigma Chemical Company, St. 
Louis, MO. 1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihy- 
drochloride (H-7) and N-(2-guanidinoethyl)-5-isoquinolinesulfona- 
mide hydrochloride (HA1004) were from Seikagaku Kogyo Co., To- 
kyo. All other chemicals were analytical reagents. 
2.2. Cell culture and treatment 
Human uterine cervical cells were prepared as described previously 
[9] and maintained in MEM/10% (v/v) fetal bovine serum until con- 
fluence. Confluent cervical fibroblasts were treated with cytokines and/ 
or chemical compounds in serum-free MEM containing 0.2% (w/v) 
lactalbumin hydrolysate to examine the production of proMMPs. In 
this series of experiments, human uterine cervical fibroblasts were 
used at passage level from the 2nd to the 10th and the passage levels 
did not affect responsiveness to cytokines and chemical reagents. In 
addition, more than three experiments were repeated using cells at 
different passage levels with different sources. 
2.3. Gelatin zymography 
The activity of gelatinolytic enzyme in culture media was detected 
by electrophoresis in 7.5% (w/v) acrylamide gel co-polymerized gelatin 
(DIFCO Laboratories, Detroit, MI) at a final concentration of 0.6 
mg/ml. Briefly, a 10 gl portion of harvested culture media was mixed 
with SDS-PAGE sample buffer [10] and then electrophoresed without 
boiling under non-reducing conditions. After electrophoresis, the gels 
were washed at room temperature for 1 h in 2.5% (v/v) Triton X-100/ 
50 mM Tris-HCl/5 mM CaCI2/I gM ZnCI~ (pH 7.5) to remove SDS 
and incubated at 37°C in the same buffer without Triton X-100, and 
then stained in 0.1% (w/v) Coomassie Brilliant Blue R-250. Clear 
zones of gelatin lysis against blue background stain indicated the 
presence of gelatinolytic enzyme. 
2.4. Western blot analysis 
ProMMP-9 in culture media was analyzed by Western blot analysis 
using polyclonal sheep anti-(human proMMP-9)antibody which was 
raised against proMMP-9 purified from HT-1080 fibrosarcoma cells 
as described previously [11]. Similarly, proMMP-3 was detected with 
polyclonal sheep anti-(human MMP-3)antibody [12]. The samples col- 
lected from triplicate wells of each treatment were concentrated with 
final 3.3% (w/v) trichloroacetic a id, dissolved in SDS-PAGE sample 
buffer in the presence of 2-mercaptoethanol, and subjected to SDS- 
PAGE (7.5% for proMMP-9 and 10% for proMMP-3). The proteins 
separated by SDS-PAGE were electrotransferred to a nitrocellulose 
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filter, and the filter was reacted with sheep anti-(human proMMP-9) 
or anti-(human MMP-3)antibody which was then complexed with 
alkaline phosphatase-conjugated donkey anti-(sheep IgG)IgG. Immu- 
noreactive proMMP-9 and proMMP-3 were visualized indirectly 
using 5-bromo-4-chloro-3-indolyl phosphate and Nitro Blue Tetrazo- 
lium as described previously [9]. 
3. Results 
3.1. Induction of proMMP-9 in human uterine cervical 
fibroblasts by TNF~t 
The expression of gelatinolytic activities by human uterine 
cervical fibroblasts was first examined by gelatin zymography 
(Fig. 1). While the 72-kDa progelatinase (proMMP-2/proge- 
latinase A) was constitutively expressed, a new gelatinolytic 
activity around 92 kDa was detected when the cells were treat- 
ed with rhTNFa. TPA (10 nM), which induces proMMP-9 in 
several cell types [1], also stimulated the cells to produce the 
gelatinolytic activity of the same molecular mass. The 92-kDa 
gelatinolytic activity was completely inhibited by 5 mM 
EDTA, but not by 1 mM diisopropylfluorophosphate (data 
not shown). These results together with immunological studies 
indicate that the induced enzyme is proMMP-9 (see Fig. 3). 
3.2. Suppression of the TNFo~-induced production of 
proMMP-9 by 1L-lo~ 
Next we examined the combined effect of TNFet and IL-lct 
on the production of proMMP-9 in human uterine cervical 
fibroblasts. Unexpectedly, the co-treatment of the cells with 
rhTNFct and rhlL-lct suppressed the rhTNFct-induced 
proMMP-9 production in a dose-dependent manner, while 
rhlL-ltx alone did not induce proMMP-9 (Fig. 2). Western 
blot analysis howed that the biosynthesis of proMMP-9 was 
increased by rhTNFt~, which was decreased by rhlL-let (Fig. 
3A). By contrast, the production of proMMP-3 was further 
enhanced when the cells were treated with both rhTNFct and 
rhlL-lct (Fig. 3B). 
On the other hand, the TPA-induced proMMP-9 was dif- 
ferently modulated by IL-lct. As shown in Figs. 2 and 3A, 
rhlL-lct synergistically enhanced the TPA-induced proMMP- 
9 production in a dose-dependent manner. Similarly, the 
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Fig. 1. TNFct induced the production of proMMP-9 in human uter- 
ine cervical fibroblasts. Confluent human uterine cervical fibroblasts 
at the 8th passage were treated with 0.2% (w/v) lactalbumin hydro- 
lysate/MEM containing rhTNFct (0.001-10 ng/ml) and TPA (10 
nM) for 2 days. Aliquots (10 ~tl) of harvested culture media were 
subjected to gelatin zymography as described in Section 2. More 
than three independent experiments were reproducible and typical 
data are shown. HT, pure proMMP-9 (1 ng/lane) of HT-1080 fibro- 
sarcoma cells. Lane 1, control; lanes 2-4, cells treated with rhTNFot 
(0.001, 0.1 and 10 ng/ml, respectively); and lane 5, cells treated with 
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Fig. 2. Regulation of the TNFct- and TPA-induced proMMP-9 
production by IL-lct in human uterine cervical fibroblasts. Conflu- 
ent cervical fibroblasts at the 6th passage were treated with rhTNFct 
(10 ng/ml), TPA (10 nM) and/or rhlL-lo~ (0.001-10 ng/ml) for 
2 days, and the culture media were analyzed for the expression of 
gelatinolytic enzyme. Aliquots of the media (10 /al) were subjected 
to gelatin zymography to detect gelatinolytic a tivity as described in
Section 2. More than three independent experiments were reproduci- 
ble and typical data are shown. Lane 1, control; lane 2, rhTNFt~ 
(10 ng/ml); lanes 3-5, rhTNFct (10 ng/ml) plus rhlL-lct (0.001, 0.1 
and 10 ng/ml, respectively); lane 6, TPA (10 nM); lanes 7-9, TPA 
(10 nM) plus rhlL-lct (0.001, 0.1 and 10 ng/ml, respectively); and 
lanes 10-12, rhlL-lo~ (0.001, 0.1 and 10 ng/ml, respectively). 
rhIL-ltx in a similar manner as in the case of the rhTNFc~- 
treated cells. These results suggested that the regulation of 
proMMP-9 production by TNFct is different from that by 
TPA in human cervical fibroblasts, and that the suppressive 
effect of IL-lct is specific on the TNFtx-induced production of 
proMMP-9. 
3.3. Effect of staurosporine on the TNFa- and TPA-induced 
production of proMMPs-9 and -3 in the presence or the 
absence of IL-loL 
Since TPA, a well characterized activator of protein kinase 
C (PKC) [13], is an effective enhancer of proMMP-9 produc- 
tion in our culture system (Fig. 1) and other cell systems [1], 
we examined whether activation of PKC is required for the 
expression of proMMP-9 in human uterine cervical fibro- 
blasts. This was approached by using PKC inhibitor as shown 
in Table 1; staurosporine at concentrations of 5-20 nM did 
not affect the induction of proMMP-9 by rhTNFa, but the 
same concentrations of this compound caused a significant 
suppression of the TPA-induced proMMP-9 production with 
A ) roMMP-9  
1 2 3 4 5 6 
B :~=:p ro MMP-3 
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Fig. 3. Western blot analysis of proMMP-9 and proMMP-3 pro- 
duced by human uterine cervical fibroblasts. Confluent cervical fi- 
broblasts at the 3rd passage were treated with rhTNFt~ (10 ng/ml), 
TPA (10 nM) and/or rhIL-lct (10 ng/ml) for 18 h. The harvested 
culture media were subjected to Western blotting to detect 
proMMP-9 (A) and proMMP-3 (B) using the specific antibodies as 
described in Section 2. More than three independent experiments 
were reproducible and typical data are shown. The shadow visua- 
lized close to the main band corresponding to proMMP-9 was con- 
firmed to be non-specific because it was also detected by non-im- 
mune sheep IgG instead of the antibody against proMMP-9. Lane 
l, control; lane 2, rhTNFt~ (10 ng/ml); lane 3, rhTNFtx (10 ng/ml) 
plus rhIL-1ct (10 ng/ml); lane 4, TPA (10 nM); lane 5, TPA (10 
nM) plus rhIL-lcc (10 ng/ml); and lane 6, rhIL-lot (10 ng/ml). 
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Table 1 
Effect of staurosporine on TNFc~- and TPA-induced proMMPs-9 
and -3 production in human uterine cervical fibroblasts 
Relative Induction (-fold) 
proMMP-9 proMMP-3 
Control N.D. 1.0 
rhTNFc~ (10 ng/ml) 1.0 7.6 
+ Staurosporine (5 nM) 1.3 ~ 5.1 
+ Staurosporine (10 nM) 1.3 ~ 2.7 
+ Staurosporine (20 nM) 1.0 ~ 2.1 
"I~A (10 nM) 1.0 3.1 
+ Staurosporine (20 nM) 0.1 b 1.3 
S~aurosporine (20 nM) N.D. 0.8 
onfluent cervical fibroblasts at the 6th passage were treated with 
r TNFc~ (10 ng/ml) or TPA (10 nM) in the presence ofstaurosporine 
(-:-20 nM) for 18 h. The harvested culture media were analyzed for 
t!e production of proMMP-9 and proMMP-3 by Western blot ana- 
l) sis. Their relative amounts were quantified by densitometric s an- 
n ng and expressed taking the rhTNFet- or TPA-induced value as 1 
f ,r proMMP-9 and the control value of proMMP-3 as 1. Three in- 
d ~pendent experiments were reproducible and typical data are shown. 
a 'Relative comparison against the rhTNF~-and TPA-induced 
F-oMMP-9, respectively. N.D., not detected. 
~ maximal inhibition of 86%. In contrast, rhTNFa-induced 
FroMMP-3 production was inhibited by staurosporine with 
maximal inhibition of 83% (calculated after subtraction of 
l i~e control value) at 20 nM. The TPA-induced proMMP-3 
t roduction was also decreased by 85% at the same concentra- 
1 on. 
As shown in Table 2, staurosporine completely diminished 
t ae rhlL-la-mediated suppression of the proMMP-9 produc- 
tion to the level of the cells treated with rhTNFc~ alone. The 
l,roduction of proMMP-3 enhanced by the co-treatment with 
~ hTNFc~ and rhlL-lc~ was also decreased by staurosporine by
'8% at the concentration f 20 nM. In addition, the enhanced 
t,roduction of proMMP-9 by the co-treatment of rhlL-lct and 
"PA was inhibited by staurosporine. Similar results were also 
, ,btained with another PKC inhibitor, H-7 but not with 




IL- la and TNFa are cytokines that evoke matrix degrada- 
tion by inducing the responsive proteinases [16]. Our previous 
study [12] has shown that IL-lc~ stimulates the cervical cells to 
produce proMMPs-1 and -3. In this report, we demonstrated 
that the action of IL-lc¢ on proMMP-9 production was dif- 
ferent from that of TNFa:  IL-lc~ preferentially modulates the 
production of proMMPs-1 and -3, but not that of proMMP- 
9; TNFc~, on the other hand, functions as an effective inducer 
of the three proMMPs. In addition, while the production of 
proMMP-2 was not altered by treating the cells with TNFe~, 
IL-I~ and TPA, these treatments slightly stimulated the acti- 
vation of proMMP-2 (Figs. 1 and 2). Recently, it has been 
shown that proMMP-2 is activated by a membrane associated 
MMP, MT-MMP [17]. Therefore, it is likely that the increase 
in the active form of MMP-2 after TNFct, IL- la or TPA 
treatment may be mediated by an increased activity of MT- 
MMP. However, the combination of TNF~ and IL-lc~, and 
TPA and IL- la did not change either the production or the 
activation of proMMP-2. Taken together these results indicate 
that the productions of proMMP-2, proMMP-3 and 
proMMP-9 by TNFc¢, IL-lc~ and TPA are differently regu- 
lated. 
Little information is available regarding the signal trans- 
duction mechanism through which the production of 
proMMP-9 is mediated on cytokine stimulation. Recent stud- 
ies have indicated that expression of proMMP-9 is regulated 
by PKC pathway in tumor cells [18,19] and T-lymphocytes 
[20,21]. In cervical fibroblasts, TNFc~ induced the production 
of proMMP-3 through PKC pathway as previous paper by 
Brenner et al. [22]. However, the TNFc¢-induced proMMP-9 
production is independent of PKC activation. This was 
further confirmed by down-regulation f PKC in which the 
cells were pretreated with TPA (100 nM) for 24 h prior to 
stimulation with TNFa (T. Sato, A. Ito and Y. Mori, unpub- 
lished data). The PKC-independent signal pathway of TNFc~ 
has been reported for other cells [23-25]. Thus, we conclude 
that in cervical fibroblasts TNFa possesses at least two dis- 
tinct signal transduction pathways after binding to its recep- 
tor: one is a PKC-independent pathway which leads to aug- 
mentation of the proMMP-9 production; and the other is the 
~able 2
Involvement of PKC in IL-I~ regulation of proMMPs-9 and -3 production in human uterine cervical fibroblasts 
Relative Induction (-fold) 
proMMP-9 proMMP-3 
Control N.D. 1.0 
~hTNFc¢ (10 ng/ml) 1.0 10.2 
hTNFc~ (10 ng/ml) + rhlL-lc~ (10 ng/ml) N.D. 16.6 
+ Staurosporine (5 nM) 0.1 ~ 14.5 
+ Staurosporine (10 nM) 0.6 ~ 7.1 
+ Staurosporine (20 nM) 1.3 ~ 4.5 
I'PA (10 nM) 1.0 3.4 
FPA (10 nM) + rhlL-lct (10 ng/ml) 6.7 t' 13.1 
+ Staurosporine (20 nM) 2.3 b 4.1 
"hlL-lo~ (10 ng/ml) N.D. 8.3 
gtaurosporine (20 nM) N.D. 0.9 
Confluent cervical fibroblasts at the 3rd passage were treated with rhTNF~ (10 ng/ml), TPA (10 nM) and/or hlL-loc (10 ng/ml) in the presence of
~taurosporine (5-20 nM) for 18 h. The harvested culture media were analyzed for the production of proMMP-9 and proMMP-3 by Western blot 
.malysis. Their relative amounts were quantified by densitometric s anning and expressed taking the rhTNFc~- or TPA-induced value as 1 for 
igroMMP-9 and the control value of proMMP-3 as 1. Three independent experiments were reproducible and typical data are shown. 
~bThe relative comparison against the rhTNFc¢- and TPA-induced proMMP-9, respectively. N.D., not detected. 
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PKC-dependent pathway that stimulates the proMMP-1 and 
proMMP-3 gene expression, 
A most striking finding in the present study is that the 
TNFtx-induced proMMP-9 in the cervical fibroblasts was sup- 
pressed by IL-lct. Cytokines are known to cause various bio- 
logical activities cooperatively rather than singly. In this re- 
gard, the TNFcx-induced proMMP-3 in the cervical cells is 
further augmented in the presence of IL-ltx. A similar obser- 
vation was made on the proMMP-3 expression for rheuma- 
toid human synovial fibroblasts [26]. However, this is not the 
case with proMMP-9. Although the suppressive mechanism of 
the TNFct-induced proMMP-9 by IL-l~t cannot be explained 
at the moment, the antagonizing effect of IL-let against he 
stimulatory activity of TNFt~ on proMMP-9 production 
shown here is a novel biological property of IL-I~. 
In contrast o TNFet, TPA together with IL-lct synergisti- 
cally enhanced the production of proMMP-9. A similar aug- 
mentation effect of TPA and IL-1 on proMMP-9 production 
was also observed in rabbit articular chondrocytes [11]. The 
difference between the effects of TNFct and TPA can be ex- 
plained by distinct intracellular signal pathways, i.e., PKC 
dependency as demonstrated here (Table 1). 
It has been reported that IL-1 induces the proMMP-9 pro- 
duction in human fibroblasts and in rabbit articular chondro- 
cytes [6,27]. However, a significant induction of proMMP-9 
by IL-1 and/or TNFct was not observed in human skin and 
synovial fibroblasts, although both cytokines enhanced the 
production of proMMPs-1 and -3 in those cells (T. Sato, 
A. Ito and Y. Mori, unpublished ata), PKC activation was 
found to be necessary for the IL-lct-mediated induction of 
proMMP-3 and suppression of proMMP-9 (Table 2). The 
involvement of PKC in the IL-lct-regulated proMMP-3 pro- 
duction is consistent with our previous work [28]. Neverthe- 
less, while IL-lct activates PKC and the stimulation of 
proMMP-9 production by combination of TPA and IL-let 
is mediated by PKC, IL-let alone does not evoke the 
proMMP-9 production in the cervical fibroblasts. The differ- 
ent cellular ability to produce a different set of proMMPs in 
response to cytokines is most likely reflected from cell specific 
intracellular signaling pathways. 
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